Clinical Trial

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

Study acronym: REDEFINE-HF
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients hospitalized with acute decompensated heart failure (HF) and mildly reduced or preserved left ventricular ejection fraction.
Protocol Amendment History 3 changes
notable Trial sites expanded: 299 -> 315 locations 2026-07-07
notable Trial sites expanded: 156 -> 299 locations 2026-05-07
notable Trial sites expanded: 80 -> 156 locations 2026-04-30
Trial Details
NCT Number NCT06008197
Lead Sponsor Colorado Prevention Center
Collaborators: St. Luke's Hospital, Kansas City, Missouri, Bayer
Conditions Heart Failure, Acute Heart Failure
Enrollment 5,200 participants
Start Date 2024-01-17
Primary Completion 2027-11 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-06